Home › Funds › Sicart Associates LLC › CGON

Sicart Associates LLC position in CGON

CG ONCOLOGY INC · Health Care

Sicart Associates LLC reported holding 25,000 shares of CGON (CG ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.36% of its reported portfolio and ranking #42 among its reported holdings. Sicart Associates LLC has disclosed CGON holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)25.00K sh
Reported value held$1.50M
Portfolio Weight0.36%
First reportedQ1 2024
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Sicart Associates LLC's CGON position evolved

Sicart Associates LLC first disclosed a stake in CGON in Q1 2024 at 25,000 shares (US$1.1M). The position peaked in Q2 2026 at 25,000 shares, worth US$1.8M. Across 11 filings, Sicart Associates LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 25,000 shares valued at US$1.5M.

Quarter by quarter

QuarterSharesValueChange
Q1 2024 25.00K $1.10M New
Q2 2024 25.00K $789.25K Hold
Q3 2024 25.00K $943.25K Hold
Q4 2024 25.00K $717.00K Hold
Q1 2025 25.00K $612.25K Hold
Q2 2025 25.00K $650.00K Hold
Q3 2025 25.00K $1.01M Hold
Q4 2025 25.00K $1.04M Hold
Q1 2026 25.00K $1.69M Hold
Q2 2026 25.00K $1.78M Hold
Q3 2026 25.00K $1.50M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CGON and 13F data

CGON (CG ONCOLOGY INC) is a Health Care company. 51 other funds we track also report a position in CGON — the largest reported positions include RTW INVESTMENTS, LP (US$605.0M), Decheng Capital LLC (US$452.7M), TCG Crossover Management, LLC (US$260.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CGON

All CGON fund holders →

FAQ

How long has Sicart Associates LLC held CGON?

Sicart Associates LLC has disclosed CGON holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Sicart Associates LLC's current position in CGON?

As of Q3 2026, Sicart Associates LLC holds 25.00K shares of CGON (CG ONCOLOGY INC), valued at $1.50M, representing 0.36% of its reported portfolio and ranking #42.

Has Sicart Associates LLC been buying or selling CGON?

In the latest 13F filing (Q3 2026), Sicart Associates LLC held unchanged its position in CGON. The position peaked in Q2 2026 at 25.00K shares.

Which other funds hold CGON?

Other major institutional holders of CGON include RTW INVESTMENTS, LP, Decheng Capital LLC, TCG Crossover Management, LLC, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.